- BofA is monitoring Hims & Hers' performance and revenue guidance, which is built around Novo Nordisk's Wegovy drug.
- Novo Nordisk offered its Wegovy drug through the platform of Hims & Hers Health, while the company also faced legal pressure from Novo Nordisk.
Hims & Hers Health partnered with Novo Nordisk to add liraglutide and Wegovy, drawing analyst scrutiny and strategic inquiries.
1 report, 0 independent
Updated Jul 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Hims & Hers Health partnered with Novo Nordisk to add liraglutide and Wegovy, drawing analyst scrutiny and strategic inquiries.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Novo Nordisk offered its Wegovy drug through the platform of Hims & Hers Health, while the company also faced legal pressure from Novo Nordisk.Also in this story
- Hims & Hers challenged Novo Nordisk's ruling regarding drug compounding.
- Hims & Hers Health has entered the generic drug market, coinciding with the expiration of Novo Nordisk's patent and the failure of a maintenance fee.
The entities involved
-
Hims & Hers Health
American telehealth company
Nothing else this week.
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Novo Nordisk launched its Wegovy pill in the German market.
Coverage
Newest first; wire copies grouped- Unknown outlet